Seres Therapeutics' SER — 428 reduces gut pathogens up to 1,000 — fold in preclinical studies
Seres Therapeutics reported SER-428 reduced gastrointestinal Enterococcus faecium and Klebsiella pneumoniae abundance by up to 1,000-fold in preclinical models. The investigational liquid live biotherapeutic targets bloodstream infection risk in critically ill patients; its formulation remained stable following simulat